-

IonQ Investor News: Robbins LLP is Investigating IonQ, Inc. (IONQ) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating IonQ (NYSE: IONQ) and its officers and directors to determine whether they breached their fiduciary duties or violated securities laws by failing to disclose material information about the development and effectiveness of its computers to shareholders. IonQ purports to "develop quantum computers designed to solve the world's most complex problems."

If you would like more information about our investigation of IonQ, Inc.'s misconduct, click here.

What is this Case About: According to the complaint, on September 30, 2021, IonQ became a public entity via business combination with dMY Technology Group, Inc. III, a special purpose acquisition company. On May 3, 2022, Scorpion Capital released a research report alleging, among other things, that IonQ is a “scam built on phony statements about nearly all key aspects of the technology and business.” It further claimed that the Company reported “[f]ictitious ‘revenue’ via sham transactions and related-party round-tripping.” On this news, the Company’s stock fell $0.71, or 9%, to close at $7.15 per share on May 3, 2022, on unusually heavy trading volume.

During the class period, defendants failed to disclose to investors that: (1) IonQ had not yet developed a 32-qubit quantum computer; (2) the Company’s 11-qubit quantum computer suffered from significant error rates, rendering it useless; and (3) IonQ’s quantum computer is not sufficiently reliable, so it is not accessible despite being available through major cloud providers. Defendants also failed to disclose that a significant portion of IonQ’s revenue was derived from improper round-tripping transactions with related parties.

Next Steps: If you acquired shares of IonQ, Inc. (IONQ) securities between March 30, 2021 and May 2, 2022, you have legal options. Contact Robbins LLP for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against IonQ, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:IONQ

Release Summary
IonQ, Inc. (IONQ) may have failed to disclose material information about the development and effectiveness of its computers to shareholders.
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

LKQ Corporation Class Action Reminder - Robbins LLP Encourages LKQ Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired LKQ Corporation (NASDAQ: LKQ) common stock between February 27, 2023 and July 23, 2025. LKQ is a global distributor of alternative collision replacement parts, recycled engines, and other vehicle components for the repair of automobiles.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.Wha...

Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

POET Technologies Inc. Class Action Reminder - Robbins LLP Encourages POET Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photoni...
Back to Newsroom